4/A: Fulcrum Therapeutics Director Amends Stock Sale Price

Fulcrum Therapeutics Director Robert J. Gould filed an amended Form 4 to correct the weighted average price of a 15,000-share stock sale.

Summary

• Robert J. Gould, a Director of Fulcrum Therapeutics, Inc. (FULC), filed an amendment to a previously submitted Form 4.
• The amendment corrects the weighted average price for the sale of 15,000 shares of common stock that occurred on January 2, 2026.
• The corrected weighted average price is $10.8726, adjusted from the $11.8726 reported in the original filing.
• The shares were sold in multiple transactions at prices ranging from $10.60 to $11.33.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.
• Following this transaction, Robert J. Gould beneficially owns 469,864 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is an administrative amendment to correct a previously reported sale price, not indicative of new operational or financial performance.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, even those under a Rule 10b5-1 plan, are routinely monitored by investors for potential signals regarding management's confidence in the company's future. This amendment, however, is purely administrative, correcting a price detail rather than announcing a new transaction or strategic shift.

Related Party Transactions

• Sale of 15,000 shares of common stock by Director Robert J. Gould on January 2, 2026, at a weighted average price of $10.8726, pursuant to a Rule 10b5-1 trading plan.

Stakeholder Impact

• Shareholders: The correction of the sale price provides accurate public information regarding an insider transaction, ensuring transparency.

Key Dates

Recommendation

The filing is an administrative amendment correcting a previously reported insider stock sale price. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The sale itself was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not necessarily a reaction to new material non-public information.

Keywords

Fulcrum Therapeutics, FULC, Form 4/A, Insider Trading, Stock Sale, Director, Robert J. Gould, 10b5-1 Plan, SEC Filing